221 related articles for article (PubMed ID: 36516256)
1. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.
Li Y; Moriyama T; Yoshimura S; Zhao X; Li Z; Yang X; Paietta E; Litzow MR; Konopleva M; Yu J; Inaba H; Ribeiro RC; Pui CH; Yang JJ
Sci Adv; 2022 Dec; 8(50):eadd6403. PubMed ID: 36516256
[TBL] [Abstract][Full Text] [Related]
2. Cytofluorimetric assay to investigate variability in blinatumomab
Braidotti S; Franca R; Granzotto M; Piscianz E; Tommasini A; Rabusin M; Stocco G; Decorti G
Front Biosci (Landmark Ed); 2022 Jan; 27(2):39. PubMed ID: 35226982
[TBL] [Abstract][Full Text] [Related]
3. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
4. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Zhao Y; Aldoss I; Qu C; Crawford JC; Gu Z; Allen EK; Zamora AE; Alexander TB; Wang J; Goto H; Imamura T; Akahane K; Marcucci G; Stein AS; Bhatia R; Thomas PG; Forman SJ; Mullighan CG; Roberts KG
Blood; 2021 Jan; 137(4):471-484. PubMed ID: 32881995
[TBL] [Abstract][Full Text] [Related]
5. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
[TBL] [Abstract][Full Text] [Related]
6. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
7. Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma.
Ivanov V; Farnault L; Mercier C; Colavolpe C; Venton G; Colle J; Lepidi H; Arnoux I; Nicolino-Brunet C; Berda-Haddad Y; Fanciullino R; Ivanov G; Costello R
Leuk Lymphoma; 2020 May; 61(5):1230-1233. PubMed ID: 31900013
[No Abstract] [Full Text] [Related]
8. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
9. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.
Novakova M; Zaliova M; Fiser K; Vakrmanova B; Slamova L; Musilova A; Brüggemann M; Ritgen M; Fronkova E; Kalina T; Stary J; Winkowska L; Svec P; Kolenova A; Stuchly J; Zuna J; Trka J; Hrusak O; Mejstrikova E
Haematologica; 2021 Aug; 106(8):2066-2075. PubMed ID: 32646889
[TBL] [Abstract][Full Text] [Related]
10. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
Fouad FM; Eid JI
Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
[TBL] [Abstract][Full Text] [Related]
11. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
12. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Chang J; Shen YJ; Shi T; Wang HF; Jin J; Zhu HH
Ann Hematol; 2023 May; 102(5):1275-1277. PubMed ID: 36892592
[No Abstract] [Full Text] [Related]
14. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A; Mikhailova E; Komkov A; Gaskova M; Abasov R; Matveev E; Kazanov M; Mamedov I; Shmitko A; Belova V; Miroshnichenkova A; Illarionova O; Olshanskaya Y; Tsaur G; Verzhbitskaya T; Ponomareva N; Bronin G; Kondratchik K; Fechina L; Diakonova Y; Vavilova L; Myakova N; Novichkova G; Maschan A; Maschan M; Zerkalenkova E; Popov A
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409391
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.
Mikhailova E; Gluhanyuk E; Illarionova O; Zerkalenkova E; Kashpor S; Miakova N; Diakonova Y; Olshanskaya Y; Shelikhova L; Novichkova G; Maschan M; Maschan A; Popov A
Haematologica; 2021 Jul; 106(7):2009-2012. PubMed ID: 33375769
[TBL] [Abstract][Full Text] [Related]
17. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
18. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
19. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Bumma N; Papadantonakis N; Advani AS
Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
[TBL] [Abstract][Full Text] [Related]
20. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
